cis-3,4-dimethyltetrahydropyran | 81554-09-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: cis-3,4-dimethyltetrahydropyran
• 英文别名: (3S,4S)-3,4-dimethyloxane
• CAS: 81554-09-8
• 化学式: C₇H₁₄O
• 分子量: 114.188
• InChiKey: WYQJZACIHYTKGC-NKWVEPMBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2,3-二甲基戊烷-1,5-二醇 在 Amberlyst 15 作用下， 生成 cis-3,4-dimethyltetrahydropyran 、 trans-3,4-dimethyltetrahydropyran
  参考文献：
  名称：

  Conformational analysis. 42. Monosubstituted tetrahydropyrans

  摘要：

  DOI：

  10.1021/ja00377a015

文献信息

• POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE
  申请人：Gilead Sciences, Inc.

  公开号：US20160176870A1

  公开（公告）日：2016-06-23

  Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (Ia): including stereoisomers and pharmaceutically acceptable salts thereof, wherein A′, R 1 , R 2 and R 3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  披露了用于治疗人类免疫缺陷病毒（HIV）感染的化合物。这些化合物具有以下的化学式（Ia）：包括立体异构体和其药用可接受的盐，其中A′、R1、R2和R3如本文所定义。还披露了与这些化合物的制备和使用相关的方法，以及包含这些化合物的药物组合物。
• LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS
  申请人：Qiao X Jennifer

  公开号：US20070135428A1

  公开（公告）日：2007-06-14

  The present application describes lactam-containing cyclic diamines and derivatives thereof of Formula I: P 4 -M-M 4 I or pharmaceutically acceptable salt forms thereof, wherein M is a non-aromatic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

  本申请描述了公式I：P4-M-M4I或其药学上可接受的盐形式的含有内酰胺的环状二胺及其衍生物，其中M为非芳香族碳环或杂环。本发明的化合物可用作胰蛋白酶样丝氨酸蛋白酶的抑制剂，特别是Xa因子的抑制剂。
• [EN] COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS<br/>[FR] COMPOSÉS POUR LE TRAITEMENT D'INFECTIONS VIRALES
  申请人：MERCK PATENT GMBH

  公开号：WO2022079250A1

  公开（公告）日：2022-04-21

  The present invention encompasses Syk inhibitor for use in the treatment of coronavirus infections, including COVID-19, alone or in combination with one or more additional therapeutic agents.

  本发明涵盖Syk抑制剂的使用，用于治疗冠状病毒感染，包括COVID-19，单独使用或与一个或多个其他治疗剂联合使用。
• FGFR4 inhibitor and preparation method and use thereof
  申请人：GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD

  公开号：US11008292B2

  公开（公告）日：2021-05-18

  Provided are a class of compounds as shown in formula (I) as FGFR4 inhibitors, and pharmaceutically acceptable salts thereof, preparation methods therefor and the use thereof in the preparation of drugs for treating FGFR4-related diseases.

  本发明提供了一类如式（I）所示的 FGFR4 抑制剂化合物及其药学上可接受的盐、其制备方法以及在制备治疗 FGFR4 相关疾病的药物中的用途。
• C5-C6 OXACYCLIC-FUSED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE
  申请人：Cumming Jared N.

  公开号：US20140023668A1

  公开（公告）日：2014-01-23

  In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula: (I) and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomeros and said stereoisomers, wherein each of ring A, ring B, ring C, R 2 , R 3 , R 4 , m, n, p, and -L 1 - is as defined herein. The novel compounds of the invention may be useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including Alzheimer's disease, are also disclosed.